Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

hibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in multiple myeloma as monotherapy, in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the potential for Kosan to receive milestone payments and royalties from the license agreement with Pfizer; the further development and potential safety, efficacy and commercialization of Kosan's product candidates, including without limitation PF-04548023 and other compounds from Kosan's motilin agonist program; and development plans with respect to PF-04548023 and the timing thereof. There are a number of
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
(Date:7/10/2014)... Biomedical Research Institute (IDIBELL) and the Catalan Institute of ... new therapeutic combination to combat resistant sarcomas. The clinical ... stabilize the growth of these tumors have been published ... ., Sarcomas , Sarcomas are a rare type ... It can affect from children to older ages. It ...
(Date:7/9/2014)... The World Health Organization recommends that youth participate in ... physical activity (MVPA) each day. Studies have shown ... hours. Therefore, it stands to reason that increasing ... In a new study scheduled for publication in The ... spent outdoors after school was positively associated with MVPA. ...
Breaking Medicine News(10 mins):Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2
... June 4 The Minneapolis-St. Paul office of Weber ... Program to head the organization,s largest annual awareness campaign. ... 8-22, will work to reach a diverse audience of ... thousands of people with leukemia and other life-threatening diseases, ...
... June 4 A cooking revolution is underway in the Kiboga district ... that the double Rocket Lorena stove is making it easier to cook ... money maker for youth in the community and are not as harmful ... out a local mixture of grass, water and mud. And for youth ...
... Mich. At the ends of chromosome are special pieces of ... caps off a shoelace. The telomeres send signals to the cells ... that should be repaired. Over time, as cells reproduce, the ... cells then have a higher risk of mutating into cancer. ...
... congestion is an important mediator in heart failure, reports ... Journal of Cardiac Failure ( http://www.onlinejcf.com/ ), published ... venous endothelium is a key regulator of central blood ... The present study demonstrates that in venous endothelium, ...
... ... Approval , ... June 4, 2009-- A new wrinkle-smoother will be arriving in doctors, offices in July: ... Union, Brazil, Argentina and more than 26 countries worldwide is a form of botulinum ...
... Nutrition Program from Fitness Expert Monique Hollowell , ... their bodies will never be the same following pregnancy ... pregnancy, less painful birth and quick recovery back to ... trainer, Monique Hollowell has created a fitness and nutrition ...
Cached Medicine News:Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 3Health News:Youth-made Stoves Provide Income, Protect the Environment 2Health News:Study gives clues to how adrenal cancer forms 2Health News:New Option for Erasing Wrinkles 2Health News:New Option for Erasing Wrinkles 3Health News:New Option for Erasing Wrinkles 4Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 3
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... distances with high Numerical Apertures, these objectives ... aberrations throughout the visible spectrum from violet ... the entire 25mm field of view. They ... reproduction, plus resolving power at the theoretical ...
Medicine Products: